BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 7, 2024
See today's BioWorld
Home
» Biogen, Abbvie tout phase III win, expect 'dac' data to satisfy FDA
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Biogen, Abbvie tout phase III win, expect 'dac' data to satisfy FDA
June 17, 2014
By
Marie Powers
No Comments
Biogen Idec Inc. looked to expand its multiple sclerosis (MS) franchise with positive top-line findings from the phase III DECIDE trial of daclizumab, in joint development with partner Abbvie Inc.
BioWorld